Dashboard
Manage Tickers

GTHXG1 Therapeutics, Inc.

Nasdaq g1therapeutics.com


$ 1.86 $ 0.81 (76.67 %)    

Monday, 24-Jun-2024 09:43:20 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 477.39 $ -1.78 (-0.37 %)
DIA $ 392.43 $ -0.03 (-0.01 %)
SPY $ 543.92 $ -0.47 (-0.09 %)
TLT $ 93.96 $ 0.21 (0.22 %)
GLD $ 215.68 $ 0.10 (0.04 %)
$ 2.48
$ 1.05
$ 1.83 x 100
$ 0.00 x 0
$ 1.05 - $ 1.86
$ 1.08 - $ 6.14
687,654
na
129.39M
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-24-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-21-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-is-cancer-focused-g1-therapeutics-stock-trading-lower-on-monday
Why Is Cancer-Focused G1 Therapeutics Stoc...
06/24/2024 13:40:08

Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC.

g1-therapeutics-preserve-2-phase-3-trial-of-trilaciclib-before-first-line-chemotherapy-in-metastatic-triple-negative-breast-cancer-did-not-achieve-statistical-significance-in-primary-endpoint-of-overall-survival
G1 Therapeutics' PRESERVE 2 Phase 3 Trial ...
06/24/2024 10:34:36

The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market. G1 is Sufficiently...

analyst-ratings-for-g1-therapeutics
Analyst Ratings For G1 Therapeutics
06/13/2024 12:00:56

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
06/13/2024 09:31:08

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
06/11/2024 17:35:23

why-applied-dna-sciences-shares-are-trading-lower-by-around-68-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Applied DNA Sciences Shares Are Tradin...
05/28/2024 17:24:16

hc-wainwright--co-reiterates-buy-on-g1-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on G1 T...
05/28/2024 16:32:53

HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
05/28/2024 16:31:12

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
05/28/2024 15:06:42

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

improvement-in-overall-survival-os-and-tolerability-seen-in-patients-receiving-trilaciclib-with-a-trop2-antibody-drug-conjugate-adc
Improvement In Overall Survival (OS) And T...
05/28/2024 10:35:17

G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the presentation of mature Phase 2 cl...

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
05/22/2024 16:15:27

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

hc-wainwright--co-reiterates-buy-on-g1-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on G1 T...
05/22/2024 12:38:45

HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.

g1-therapeutics-shares-are-trading-higher-after-the-company-and-deimos-biosciences-announced-a-licensing-agreement-for-lerociclib-for-radioprotective-uses
G1 Therapeutics shares are trading higher ...
05/22/2024 10:36:06

g1-therapeutics-and-deimos-biosciences-announced-a-global-licensing-agreement-excluding-the-asia-pacific-region-for-lerociclib-for-radioprotective-uses-g1-is-expected-to-receive-10-of-deimos-biosciences-shares-in-addition-to-a-20-sales-based-royalty
G1 Therapeutics And Deimos Biosciences Ann...
05/22/2024 10:33:00

whats-going-on-with-g1-therapeutics-stock
What's Going On With G1 Therapeutics Stock?
05/09/2024 18:24:53

According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics.  According to the r...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/09/2024 16:31:09

watching-g1-therapeutics-traders-circulate-ma-blog-suggesting-company-rumored-to-have-a-cvr-aspect-that-could-value-the-company-at-between-12-14share
Watching G1 Therapeutics; Traders Circulat...
05/09/2024 14:04:11

hc-wainwright--co-reiterates-buy-on-g1-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on G1 T...
05/02/2024 17:37:50

HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.

evaluating-g1-therapeutics-insights-from-5-financial-analysts
Evaluating G1 Therapeutics: Insights From ...
05/01/2024 18:00:58

needham-reiterates-buy-on-g1-therapeutics-maintains-12-price-target
Needham Reiterates Buy on G1 Therapeutics,...
05/01/2024 16:05:40

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)